Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier’s Onco-hematology Portfolio

Also Read

YourStory’s TechSparks makes thundering debut in Mumbai: A two-day gala featuring India’s top entrepreneurs, investors, innovators, and more

QIAGEN and Servier are collaborating to develop a PCR-based companion diagnostic test that can be used to rapidly identify AML patients with IDH1 gene mutations. This partnership comes in the light of the published pivotal clinical phase 3 data of the AGILE study which showed that ivosidenib in combination with azacitidine as a first-line treatment for intensive chemotherapy ineligible AML patients with IDH1 gene mutations shows superior results compared to treatment with azacitidine alone.[1] The partnership with QIAGEN will lead to the development of a specific diagnostic test for IDH1 gene mutations with a rapid turnaround time.

Brian Lockhart, Global Head of Companion Diagnostics at Servier, said: “In order to expand the global access for ivosidenib for patients, it is imperative that we leverage a partner such as QIAGEN with an established global footprint in oncology-driven diagnostics, and a proven expertise in companion diagnostics development and approvals.”

Jonathan Arnold, Vice President, Head of Partnering for Precision Diagnostics at QIAGEN, said: “We are pleased to support Servier with a companion diagnostic in their mission to propose innovative treatment for IDH1 mutated AML patients. At the same time, we are further strengthening our role in developing companion diagnostics for the ever-growing number of biomarkers being discovered in onco-hematology.”

[1] Results from the AGILE study were published in the New England Journal of Medicine (NEJM) in April 2022.

Media Contact: presse@servier.com

PDF – https://mma.prnewswire.com/media/2018929/PR_Servier_announces_partnership_with_QIAGEN.pdf

Logo – https://mma.prnewswire.com/media/1914957/Servier_Logo.jpg